Penserra Capital Management’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $15K | Hold |
30
| – | – | ﹤0.01% | 884 |
|
|
2026
Q1 | $14K | Sell |
30
-3
| -9% | -$1.63K | ﹤0.01% | 838 |
|
|
2025
Q4 | $19K | Hold |
33
| – | – | ﹤0.01% | 819 |
|
|
2025
Q3 | $16K | Buy |
33
+3
| +10% | +$1.4K | ﹤0.01% | 833 |
|
|
2025
Q2 | $12K | Sell |
30
-390
| -93% | -$163K | ﹤0.01% | 814 |
|
|
2025
Q1 | $208K | Sell |
420
-996
| -70% | -$539K | ﹤0.01% | 733 |
|
|
2024
Q4 | $735K | Buy |
1,416
+984
| +228% | +$541K | 0.01% | 491 |
|
|
2024
Q3 | $266K | Buy |
432
+131
| +44% | +$77.5K | 0.01% | 663 |
|
|
2024
Q2 | $167K | Buy |
301
+271
| +903% | +$155K | ﹤0.01% | 758 |
|
|
2024
Q1 | $17K | Sell |
30
-1,757
| -98% | -$986K | ﹤0.01% | 915 |
|
|
2023
Q4 | $947K | Sell |
1,787
-818
| -31% | -$396K | 0.02% | 389 |
|
|
2023
Q3 | $1.32M | Sell |
2,605
-382
| -13% | -$204K | 0.03% | 311 |
|
|
2023
Q2 | $1.56M | Buy |
2,987
+2,497
| +510% | +$1.35M | 0.03% | 324 |
|
|
2023
Q1 | $281K | Sell |
490
-52
| -10% | -$29.3K | 0.01% | 624 |
|
|
2022
Q4 | $298K | Buy |
542
+100
| +23% | +$53K | 0.01% | 609 |
|
|
2022
Q3 | $224K | Buy |
442
+366
| +482% | +$205K | 0.01% | 613 |
|
|
2022
Q2 | $41K | Sell |
76
-84
| -53% | -$46.2K | ﹤0.01% | 948 |
|
|
2022
Q1 | $93K | Buy |
160
+94
| +142% | +$54K | ﹤0.01% | 862 |
|
|
2021
Q4 | $44K | Sell |
66
-6
| -8% | -$3.75K | ﹤0.01% | 1054 |
|
|
2021
Q3 | $41K | Buy |
72
+2
| +3% | +$1.1K | ﹤0.01% | 1104 |
|
|
2021
Q2 | $35K | Buy |
+70
| New | +$33K | ﹤0.01% | 1074 |
|
|
2020
Q4 | – | Sell |
-8,607
| Closed | -$3.8M | – | 1128 |
|
|
2020
Q3 | $3.8M | Buy |
+8,607
| New | +$3.56M | 0.14% | 147 |
|
|
2019
Q3 | – | Sell |
-102
| Closed | -$29K | – | 959 |
|
|
2019
Q2 | $29K | Sell |
102
-38
| -27% | -$10.5K | ﹤0.01% | 751 |
|
|
2019
Q1 | $38K | Sell |
140
-7,469
| -98% | -$1.86M | ﹤0.01% | 579 |
|
|
2018
Q4 | $1.7M | Buy |
7,609
+5,309
| +231% | +$1.25M | 0.17% | 101 |
|
|
2018
Q3 | $561K | Buy |
2,300
+325
| +16% | +$74.8K | 0.03% | 263 |
|
|
2018
Q2 | $409K | Buy |
1,975
+75
| +4% | +$15.9K | 0.03% | 237 |
|
|
2018
Q1 | $392K | Buy |
1,900
+150
| +9% | +$31.5K | 0.04% | 188 |
|
|
2017
Q4 | $332K | Buy |
1,750
+275
| +19% | +$52.7K | 0.04% | 166 |
|
|
2017
Q3 | $282K | Buy |
1,475
+175
| +13% | +$31.7K | 0.07% | 148 |
|
|
2017
Q2 | $226K | Buy |
1,300
+150
| +13% | +$25.2K | 0.08% | 179 |
|
|
2017
Q1 | $176K | Buy |
1,150
+100
| +10% | +$15.3K | 0.02% | 232 |
|
|
2016
Q4 | $148K | Buy |
1,050
+186
| +22% | +$27.4K | 0.02% | 269 |
|
|
2016
Q3 | $137K | Buy |
864
+432
| +100% | +$66.6K | 0.02% | 212 |
|
|
2016
Q2 | $64K | Buy |
432
+144
| +50% | +$21.3K | 0.01% | 268 |
|
|
2016
Q1 | $40 | Buy |
288
+46
| +19% | +$6.17K | ﹤0.01% | 312 |
|
|
2015
Q4 | $34K | Buy |
+242
| New | +$32.3K | ﹤0.01% | 302 |
|
Other funds holding TMO
Penserra Capital Management's TMO Position: Q2 2026 in Review
Penserra Capital Management held its Thermo Fisher Scientific (TMO) position steady in Q2 2026 at 30 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #884.
Penserra Capital Management first reported a position in TMO in Q4 2015 and has held it in 37 quarters since. The position peaked at $3.8M in Q3 2020. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Penserra Capital Management held 30 shares of Thermo Fisher Scientific worth $15K as of Q2 2026.
- Penserra Capital Management left its Thermo Fisher Scientific share count unchanged in Q2 2026.
- Thermo Fisher Scientific made up ﹤0.01% of Penserra Capital Management's portfolio in Q2 2026, its #884 holding.
- Penserra Capital Management first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 37 quarters since.
- Penserra Capital Management's Thermo Fisher Scientific position peaked at $3.8M in Q3 2020.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.